Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Scholar Rock Holding (SRRK), 14,935% surge in interest
• Trevena (TRVN), 553% surge in interest
• iBio (IBIO), 245% surge in interest

Pipeline and key clinical candidates for these companies:

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with “the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis,” the company states. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path, it has noted.

Trevena is a biopharmaceutical company focused on the development and commercialization of medicines for patients with CNS disorders. The company has one approved product in the United States, OLINVYK injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The company’s pipeline includes three investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to “decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets,” the company stated.

Recent news on these stocks:

October 8

A Scholar Rock 10.265M share secondary offering priced at $28.25. The deal size was increased to $300M from $275M and the deal priced below the last closing price of $29.49. JPMorgan, Jefferies and Piper Sandler acted as joint book running managers for the offering.

October 4

Trevena announced that the company received notice that the Nasdaq Hearings Panel had determined to delist the company’s common stock from The Nasdaq Stock Market due to the company’s failure to comply with the minimum stockholder’s equity requirement under Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Panel had provided the company until October 2, to regain compliance with the Equity Standard Rule.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.